MASTER AGREEMENT by and between GILEAD SCIENCES, INC. and GILEAD SCIENCES K.K. and JAPAN TOBACCO INC. Dated as of November 29, 2018Master Agreement • April 18th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
This Master Agreement (this “Agreement”) is made and entered into as of November 29, 2018 (the “Execution Date”) and, except for certain provisions specified in Section 12.1 that will be effective as of the Execution Date, will be effective as of the Closing Date (as defined below), by and between Japan Tobacco Inc., a Japan corporation having its principal place of business at Toranomon 2-2-1, Minato-ku, Tokyo 105-8422, Japan (“JT”), on the one hand, and Gilead Sciences, Inc., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, California, CA 94404, United States (“Gilead”), and Gilead Sciences K.K., a Japan corporation having its principal place of business at Gran Tokyo South Tower 16F, Marunouchi 1-9-2, Chiyoda-ku, Tokyo 100-6616, Japan (“GSJ”), on the other hand. JT, on the one hand, and Gilead and GSJ, on the other hand, are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED EVG LICENSE AGREEMENTLicense Agreement • April 18th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • England
THIS AMENDED AND RESTATED EVG LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 29, 2018 (the “A&R Execution Date”) by and between JAPAN TOBACCO INC., a Japanese corporation having its principal place of business at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan (“JT”), and GILEAD SCIENCES, INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, United States (“Gilead”). JT and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
